MedTrace Logo

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

NCT02990481 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-04-16

No results posted yet for this study

Summary

1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent
2. To establish the dose of TRK-950 recommended for future phase 2 studies

Conditions

Interventions

BIOLOGICAL

TRK-950

Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle

BIOLOGICAL

TRK-950

Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle

BIOLOGICAL

TRK-950

Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle

Sponsors & Collaborators

  • Toray Industries, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-06
Primary Completion
2019-09-16
Completion
2019-09-16
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02990481 on ClinicalTrials.gov